159 related articles for article (PubMed ID: 9182836)
61. [Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure].
Kamata H; Asano K; Soejima K; Shirahata T; Nakatani M; Inamoto H; Iketani O; Yamayoshi Y; Tanigawara Y; Ishizaka A
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1529-32. PubMed ID: 19755826
[TBL] [Abstract][Full Text] [Related]
62. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.
Los G; Tuyt L; van Vugt M; Schornagel J; Pinedo HM
Cancer Chemother Pharmacol; 1993; 32(6):425-33. PubMed ID: 8258189
[TBL] [Abstract][Full Text] [Related]
63. New superselective intra-arterial infusion via superficial temporal artery for cancer of the tongue and tumour tissue platinum concentration after carboplatin (CBDCA) infusion.
Tohnai I; Fuwa N; Hayashi Y; Kaneko R; Tomaru Y; Hibino Y; Ueda M
Oral Oncol; 1998 Sep; 34(5):387-90. PubMed ID: 9861346
[TBL] [Abstract][Full Text] [Related]
64. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
Loh GW; Ting LS; Ensom MH
Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
[TBL] [Abstract][Full Text] [Related]
65. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Jandial DD; Messer K; Farshchi-Heydari S; Pu M; Howell SB
Gynecol Oncol; 2009 Dec; 115(3):362-6. PubMed ID: 19775736
[TBL] [Abstract][Full Text] [Related]
66. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
67. Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children.
Patoux A; Bleyzac N; Boddy AV; Doz F; Rubie H; Bastian G; Maire P; Canal P; Chatelut E
Eur J Clin Pharmacol; 2001 Jul; 57(4):297-303. PubMed ID: 11549207
[TBL] [Abstract][Full Text] [Related]
68. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
69. Pharmacokinetically guided administration of chemotherapeutic agents.
van den Bongard HJ; Mathôt RA; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2000 Nov; 39(5):345-67. PubMed ID: 11108434
[TBL] [Abstract][Full Text] [Related]
70. Clinical pharmacokinetics of carboplatin in children.
Riccardi R; Riccardi A; Lasorella A; Di Rocco C; Carelli G; Tornesello A; Servidei T; Iavarone A; Mastrangelo R
Cancer Chemother Pharmacol; 1994; 33(6):477-83. PubMed ID: 8137457
[TBL] [Abstract][Full Text] [Related]
71. Carboplatin pharmacokinetics following a single-dose infusion in sulphur-crested cockatoos (Cacatua galerita).
Filippich LJ; Charles BG; Sutton RH; Bucher AM
Aust Vet J; 2004 Jun; 82(6):366-9. PubMed ID: 15267096
[TBL] [Abstract][Full Text] [Related]
72. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.
Chatelut E; Pivot X; Otto J; Chevreau C; Thyss A; Renée N; Milano G; Canal P
Eur J Cancer; 2000 Jan; 36(2):264-9. PubMed ID: 10741287
[TBL] [Abstract][Full Text] [Related]
73. Circadian time dependence of murine tolerance for carboplatin.
Boughattas NA; Lévi F; Hecquet B; Lemaigre G; Roulon A; Fournier C; Reinberg A
Toxicol Appl Pharmacol; 1988 Nov; 96(2):233-47. PubMed ID: 3057682
[TBL] [Abstract][Full Text] [Related]
74. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
Rousseau A; Marquet P
Fundam Clin Pharmacol; 2002 Aug; 16(4):253-62. PubMed ID: 12570013
[TBL] [Abstract][Full Text] [Related]
75. Effect of hyperthermia on cisplatin and carboplatin disposition in the isolated, perfused tumour and skin flap.
Vaden SL; Page RL; Williams PL; Riviere JE
Int J Hyperthermia; 1994; 10(4):563-72. PubMed ID: 7963811
[TBL] [Abstract][Full Text] [Related]
76. Scaling adult dose and schedule of anticancer agents to children.
Dawson TH
J Cancer Res Clin Oncol; 2013 Dec; 139(12):2035-45. PubMed ID: 24072230
[TBL] [Abstract][Full Text] [Related]
77. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback.
Monjanel-Mouterde S; Ciccolini J; Bagarry D; Zonta-David M; Duffaud F; Favre R; Durand A
J Clin Pharm Ther; 2003 Apr; 28(2):109-16. PubMed ID: 12713607
[TBL] [Abstract][Full Text] [Related]
78. Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.
Vaden SL; Williams PL; Page RL; Riviere JE
Cancer Chemother Pharmacol; 1993; 32(1):31-8. PubMed ID: 8462121
[TBL] [Abstract][Full Text] [Related]
79. A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count.
Fish RG; Shelley MD; Griffiths H; Mason M; Adams M; James K
Anticancer Drugs; 1994 Oct; 5(5):527-32. PubMed ID: 7858284
[TBL] [Abstract][Full Text] [Related]
80. Potentiation of cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) by amphotericin B in BALB/c nude mice bearing human ovarian carcinoma cells.
Kojima M; Kikkawa F; Oguchi H; Tamakoshi K; Maeda O; Suganuma N; Tomoda Y
Jpn J Cancer Res; 1994 Nov; 85(11):1159-64. PubMed ID: 7829402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
